Research Article
Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
Table 1
Demographic and clinical characteristics of patients.
| | | Group A, n = 28 | Group B, n = 30 | Group C, n = 30 | |
| | Male (%) | 15 (53.6) | 14 (46.7) | 13 (43.3) | 0.73 | | Age (years) | 55 ± 19.6 | 54 ± 15.7 | 53 ± 17.2 | 0.85 | | Sepsis site (%) | | | | 0.64 | | Pulmonary | 9 (32.1) | 12 (40) | 14 (46.7) | | | Gastrointestinal | 6 (21.4) | 3 (10) | 4 (13.3) | | | Urinary | 5 (17.9) | 5 (16.7) | 4 (13.3) | | | Soft tissue | 7 (25) | 7 (23.3) | 7 (23.3) | | | Central nervous system | 1 (3.6) | 0 | 0 | | | Others | 0 | 3 (10) | 1 (3.3) | | | Comorbidities (%) | | | | 0.71 | | Neoplasia | 1 (3.6) | 4 (13.3) | 4 (13.3) | | | HIV | 3 (10.7) | 3 (10) | 2 (6.7) | | | COPD | 0 | 0 | 1 (3.3) | | | CHF | 1 (3.6) | 2 (6.7) | 3 (10) | | | DM (%) | 10 (35.7) | 16 (53.3) | 7 (23.3) | 0.05 | | Hypertension (%) | 8 (28.6) | 16 (53.3) | 12 (40) | 0.15 | | Baseline sCr (mg/dL) | 0.81 ± 0.33 | 0.87 ± 0.29 | 0.78 ± 0.24 | 0.48 | | sCr on day 1 (mg/dL) | 3.0 ± 1.7 | 3.3 ± 3.1 | 2.7 ± 1.6 | 0.60 | | Oligoanuria (%) | 3 (10.7) | 7 (23.3) | 6 (20) | 0.43 | | Septic shock (%) | 11 (39.3) | 10 (34.5) | 13 (43.3) | 0.78 | | Cardiogenic shock (%) | 4 (14.3) | 7 (23.3) | 3 (10) | 0.35 | | Surgical case (%) | 13 (46.4) | 14 (46.7) | 8 (26.7) | 0.19 | | Mechanical ventilation (%) | 10 (35.7) | 6 (20) | 10 (33.3) | 0.36 | | Randomization time (h) | 6.6 ± 7 | 5.5 ± 6.7 | 8.5 ± 11.7 | 0.40 | | SOFA score | 9 ± 2.3 | 8.7 ± 2.5 | 8.9 ± 2.5 | 0.84 |
|
|
HIV: human immunodeficiency virus; COPD: chronic obstructive pulmonary disease; CHF: chronic heart failure; DM2: diabetes mellitus.
|
